

September 1, 2025

PHC Corporation
15F DAI-ICHI LIFE HIBIYA FIRST 1-13-2 Yurakucho, Chiyoda-ku, Tokyo
100-8403, Japan

JCR Pharmaceuticals Co., Ltd.
3-19 Kasuga-cho, Ashiya, Hyogo 659-0021, Japan

**PHC and JCR GROWJECTOR® L Automated Injection Device Wins 2025
Kids Design Award**



GROWJECTOR® L

Japanese Medical Device Nomenclature: Reusable medication/vaccine injector

Marketing certificate number:228AABZX00109000

Tokyo, Japan and Hyogo, Japan – September 1, 2025 – The In Vitro Diagnostics Division of PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; "PHC IVD") and JCR Pharmaceuticals Co., Ltd. (Headquarters: Ashiya, Hyogo, Chairman, President and CEO: Shin Ashida; "JCR") today announced that the automated injection device GROWJECTOR® L has been awarded a 2025 Kids Design Award in the category of Communities and Society.

The Kids Design Awards is a Japanese award program that recognizes outstanding products, services, and initiatives in Japan, that promote children's safety, healthy development, and a child-friendly society. The award program is organized by the Kids Design Association in

cooperation with Japan's Ministry of Economy, Trade and Industry (METI). This recognition marks the first Kids Design Award for GROWJECTOR® L, since, receiving the Good Design Award in 2017. The award reflects not only its innovative design, but also the real-world value demonstrated through years of use in clinical practice.

Launched in 2017, GROWJECTOR® L is an automated injection device developed by PHC exclusively for use with JCR's subcutaneous injections of the GROWJECT® 6mg and 12mg. The device was designed to support children who require daily growth hormone therapy at home, reducing the psychological stress of self-injection for both patients and caregivers, while helping ensure treatment adherence.

Key features include:

- **Ease of use** – Fully automated needle insertion, drug delivery, and retraction for simpler, safer handling, fostering confidence in treatment.
- **Reduced anxiety** – A design that hides the needle and incorporates animations and melodies to guide injections.
- **Motivation to continue treatment** – Playful functions, such as collectible character illustrations after injections, designed to engage children.

This award reaffirms PHC IVD and JCR's commitment to developing products that support patients and healthcare professionals, and to creating an environment where every child can receive treatment safely, comfortably, and confidently through innovations in both design and function.

About the In Vitro Diagnostics (IVD) Division of PHC Corporation

Established in 1969, PHC Corporation is a Japanese subsidiary of PHC Holdings Corporation (TSE 6523), a global collection of healthcare companies that develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. With the mission to contribute to the health of society through healthcare solutions that have a positive impact and improve the lives of people, the IVD Division works to improve medical services for patients by contributing to early diagnosis and effective medical care for diseases such as diabetes and myocardial infarction through development, manufacturing, and sale of testing and analysis equipment, including blood glucose monitoring systems and POCT devices, and in-vitro diagnostics.

<https://www.phchd.com/global/ivd>

About PHC Holdings Corporation (PHC Group)

PHC Holdings Corporation (TSE 6523) is a global collection of healthcare companies with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care, Eprexia, LSI Medience Corporation, Wemex and Mediford. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group's consolidated net sales in FY2024 were JPY 361.6 billion with global distribution of products and services in more than 125 countries and regions.

www.phchd.com

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company focused on the research, development, manufacturing, and commercialization of biotherapeutics. Guided by its corporate philosophy — “We create treatments that go beyond rare disease to solve the world’s most complex healthcare challenges” — JCR leverages advanced technologies in regenerative medicine, recombinant proteins, and gene therapy. Building on nearly 50 years of experience in Japan, JCR has expanded its business operations to the United States, Europe, and Latin America. For more information, please visit JCR’s global website: <https://jcrpharm.com/>.

For product enquiries:

In Vitro Diagnostics Division of PHC Corporation

Phone: +81-70-1449-9486 / +81-70-1226-3325

E-mail: ivd-communications@gg.phchd.com

For IR and media enquiries:

Investor Relations & Corporate Communications Department

PHC Holdings Corporation

+81-3-6778-5311

E-mail: phc-pr@gg.phchd.com

IR/PR Office, Corporate Strategy Division, JCR Pharmaceuticals Co., Ltd.

Email: ir-info@jp.jcrpharm.com